

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/Caplus and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS	28	JUN 19	CAS REGISTRY includes selected substances from web-based collections
NEWS	29	JUN 25	CA/Caplus and USPAT databases updated with IPC reclassification data
NEWS	30	JUN 30	AEROSPACE enhanced with more than 1 million U.S. patent records
NEWS	31	JUN 30	EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated

organizations  
 NEWS 32 JUN 30 STN on the Web enhanced with new STN AnaVist  
 Assistant and BLAST plug-in  
 NEWS 33 JUN 30 STN AnaVist enhanced with database content from EPFULL  
 NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,  
 AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.  
 NEWS HOURS STN Operating Hours Plus Help Desk Availability  
 NEWS LOGIN Welcome Banner and News Items  
 NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that  
 specific topic.

All use of STN is subject to the provisions of the STN Customer  
 agreement. Please note that this agreement limits use to scientific  
 research. Use for software development or design or implementation  
 of commercial gateways or other similar uses is prohibited and may  
 result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 09:09:40 ON 16 JUL 2008

=> file reg  
 COST IN U.S. DOLLARS SINCE FILE TOTAL  
 ENTRY SESSION  
 FULL ESTIMATED COST 0.21 0.21

FILE 'REGISTRY' ENTERED AT 09:10:00 ON 16 JUL 2008  
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
 COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file  
 provided by InfoChem.

STRUCTURE FILE UPDATES: 15 JUL 2008 HIGHEST RN 1034171-01-1  
 DICTIONARY FILE UPDATES: 15 JUL 2008 HIGHEST RN 1034171-01-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.



TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

Please note that search-term pricing does apply when  
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and  
 predicted properties as well as tags indicating availability of  
 experimental property data in the original document. For information  
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

=>  
 Uploading C:\Program Files\Stnexp\Queries\10530571.str



```

chain nodes :
12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27
ring nodes :
1 2 3 4 5 6 7 8 9 10 11
chain bonds :
8-14 8-15 9-12 9-13 10-16 11-17 17-18 17-26 18-19 18-25 19-20 19-27
20-21 20-24 21-22 21-23
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6 5-7 6-11 7-8 8-9 9-10 10-11
exact bonds :
5-7 6-11 7-8 8-9 8-14 8-15 9-10 9-12 9-13 10-11 10-16 11-17 17-18
17-26 18-19 18-25 19-20 19-27 20-21 20-24
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6 21-22 21-23
isolated ring systems :
containing 1 :

```

```

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom
11:Atom 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS 24:CLASS 25:CLASS 26:CLASS
27:CLASS

```

L1 STRUCTURE UPLOADED

=> d 11

L1 HAS NO ANSWERS

L1

STR

\* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT \*

Structure attributes must be viewed using STN Express query preparation.

=> s l1 full

FULL SEARCH INITIATED 09:10:20 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 65 TO ITERATE

100.0% PROCESSED 65 ITERATIONS

26 ANSWERS

SEARCH TIME: 00.00.01

L2

26 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

178.36

178.57

FILE 'CAPLUS' ENTERED AT 09:10:25 ON 16 JUL 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Jul 2008 VOL 149 ISS 3

FILE LAST UPDATED: 15 Jul 2008 (20080715/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l2 full

L3 9 L2

=> d ibib abs hitstr tot

L3 ANSWER 1 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2008:639779 CAPLUS

DOCUMENT NUMBER: 149:1495

TITLE: Methods of treating neuropathic pain with agonists of PPAR- $\gamma$

INVENTOR(S): Chiang, Lillian W.; Honore, Tage

PATENT ASSIGNEE(S): Aestus Therapeutics, Inc., USA

SOURCE: PCT Int. Appl., 80pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008063842	A2	20080529	WO 2007-US83326	20071101
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2006-864095P P 20061102

OTHER SOURCE(S): MARPAT 149:1495

AB Embodiments of the invention relate to the treatment of neuropathic pain in mammals. Embodiments of the invention include methods for treating neuropathic pain as well as methods for preparing medicaments used in the treatment of mammalian pain. Preferably, methods of the invention comprise the use of PPAR- $\gamma$  agonists for the treatment of mammalian pain.

IT 280585-34-4, Oxeglitazar 280585-34-4D, Oxeglitazar, esters


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(treating neuropathic pain with agonists of PPAR- $\gamma$ )

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



ACCESSION NUMBER: 2007:1069214 CAPLUS

DOCUMENT NUMBER: 147:433271

TITLE: Supercritical Antisolvent Versus Coevaporation - Preparation and Characterization of Solid Dispersions  
 AUTHOR(S): Majerik, Viktor; Horvath, Geza; Szokonya, Laszlo; Charbit, Gerard; Badens, Elisabeth; Bosc, Nathalie; Teillaud, Eric

CORPORATE SOURCE: Department of Chemical Engineering Science, University of Pannonia, Veszprem, Hung.

SOURCE: Drug Development and Industrial Pharmacy (2007), 33(9), 975-983

CODEN: DDIPD8; ISSN: 0363-9045

PUBLISHER: Informa Healthcare

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The objective of this work was to improve the dissoln. rate and aqueous solubility

of oxeglitazar. Solid dispersions of oxeglitazar in PVP K17 (polyvinylpyrrolidone) and poloxamer 407 (polyoxyethylene-polyoxypropylene block copolymer) were prepared by supercrit. antisolvent (SAS) and coevaporation (CoE) methods. Drug-carrier formulations were characterized by powder x-ray diffraction, Fourier transform IR spectroscopy, SEM, gas chromatog., UV/VIS spectroscopy and in vitro dissoln. tests. The highest dissoln. rate (nearly 3-fold higher than raw drug) was achieved by preparation of drug/PVP K17 coevaporate. Oxeglitazar/PVP K17 solid dispersions were stabilized by hydrogen bonding but contained higher amount of residual dichloromethane (DCM) than poloxamer 407 formulations regardless of the method of preparation SAS prepared oxeglitazar/poloxamer 407 dissolved more

than two times faster than raw drug. However, unlike PVP K17, poloxamer 407 did not form a single phase amorphous solid solution with oxeglitazar which has been manifested in higher degrees of crystallinity, too. Among the two techniques, evaluated in this work, conventional coevaporation resulted in higher amorphous content but SAS reduced residual solvent content more efficiently.

IT 280585-34-4, Oxeglitazar


RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comparison of supercrit. antisolvent and coevaporation method for preparation and characterization of solid dispersions)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT: 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:1328491 CAPLUS  
 DOCUMENT NUMBER: 146:190124  
 TITLE: Bioavailability enhancement of an active substance by supercritical antisolvent precipitation  
 AUTHOR(S): Majerik, Viktor; Charbit, Gerard; Badens, Elisabeth; Horvath, Geza; Szokonya, Laszlo; Bosc, Nathalie; Teillaud, Eric  
 CORPORATE SOURCE: Department of Chemical Engineering, Pannon University, Veszprem, H-8201, Hung.  
 SOURCE: Journal of Supercritical Fluids (2007), 40(1), 101-110  
 CODEN: JSFLEH; ISSN: 0896-8446  
 PUBLISHER: Elsevier B.V.  
 DOCUMENT TYPE: Journal  
 LANGUAGE: English

AB Oxeglitazar is a new orally administered poorly water soluble active substance used in the treatment of type II diabetes. Our research aimed to improve the bioavailability of this active substance using Supercrit. Antisolvent (SAS) process. Oxeglitazar was copptd. with various solubilizing excipients: polyoxyethylene-polyoxypropylene block copolymers (Poloxamer 188 and 407), polyethylene glycol (PEG 8000) and polyvinylpyrrolidone (PVP K17) from six different solvents: Ethanol (EtOH), THF, dichloromethane (DCM), chloroform (CHCl3), N-methyl-2-pyrrolidone (NMP), dimethylsulfoxide (DMSO) and two binary solvent mixts.: EtOH/THF (50:50%, volume/volume) and EtOH/CHCl3 (50:50%, volume/volume). Formulations were compared in terms of particle morphol., crystallinity, polymorphic purity, residual solvent content, precipitation


yield and dissoln. kinetics. SAS formulations of oxeglitazar-PEG 8000, Poloxamer 188 and 407 contained acicular drug crystals that were partly embedded in polymeric spheres while expts. with PVP K17 resulted in quasi amorphous solid dispersions with high d. and good flowability. In spite of the greater particle size, SAS formulations exhibited significantly greater dissoln. rate compared to raw drug and phys. mixts. More than twice as much active substance was dissolved at 5 min from Poloxamer 407 and PVP K17 formulations than from unprocessed drug. In addition, SAS prepared Poloxamer 407 formulation from DCM solution exhibited high polymorphic purity, good flow properties, acceptable precipitation yield and low residual solvent content.

IT 280585-34-4, Oxeglitazar  
 RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (bioavailability enhancement of an active substance by supercrit. antisolvent precipitation)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.





RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

ACCESSION NUMBER: 2006:1253003 CAPLUS  
 DOCUMENT NUMBER: 146:804  
 TITLE: insulin sensitization for delaying puberty and increasing growth  
 INVENTOR(S): De Zegher, Francis; Dunger, David; Ibanez, Lourdes  
 PATENT ASSIGNEE(S): K.U. Leuven Research and Development, Belg.; Addenbrooke's Hospital  
 SOURCE: PCT Int. Appl., 61pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125285	A1	20061130	WO 2006-BE60	20060523
WO 2006125285	B1	20070111		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: GB 2005-10469 A 20050523

OTHER SOURCE(S): MARPAT 146:804

AB In accordance with the purpose of the invention, as embodied and broadly described herein, the invention is broadly drawn to a new method of treatment, the use of agents to manufacture a composition of treatment or the composition

of treatment for the prevention of rapidly progressive puberty, the prevention of early menarche or the modulation, more particularly the delay, of the tempo of puberty in a female mammal, preferably a human girl, and the disorders related thereto. In a particular embodiment the present invention involves the use of at least one insulin-sensitizing agent such as metformin, any of the polymorphs of metformin or a pharmaceutically acceptable salt thereof for the preparation of a composition

of treatment to modulate the tempo of pubertal progression in a girl. Metformin administration to girls experiencing precocious puberty resulted in normalization of pubertal progression to menarche, increased height gains, leaner body composition, and decreases indexes relating to insulin resistance.

IT 280585-34-4, Oxeglitazar


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(metformin-induced insulin sensitization for delaying puberty and increasing growth)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 5 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:1345487 CAPLUS  
 DOCUMENT NUMBER: 144:69749  
 TITLE: Preparation of 3,3-dimethylbenzoxepin-5-ylalkenones as intermediates for antidiabetic pentadienoic acids  
 INVENTOR(S): Brunet, Michel; Le Borgne, Guy  
 PATENT ASSIGNEE(S): Merck Sante, Fr.  
 SOURCE: Eur. Pat. Appl., 20 pp.  
 CODEN: EPXXDW  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1609786	A1	20051228	EP 2004-291616	20040625
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
WO 2006002721	A1	20060112	WO 2005-EP5693	20050527
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1758876	A1	20070307	EP 2005-747039	20050527
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, LV				
PRIORITY APPLN. INFO.:			EP 2004-291616	A 20040625
			WO 2005-EP5693	W 20050527
OTHER SOURCE(S):			CASREACT 144:69749; MARPAT 144:69749	
GI				



AB Title compds. [I; R = H, (substituted) alkyl, aryl; R1 = halo, cyano, NO2, CO2H, (halo)alkoxycarbonyl, etc.; p = 0-4], were prepared. Thus, 3,3-dimethyl-7-ethyl-2,3,4,5-tetrahydrobenzoxazepin-5-one, triflic anhydride, and pyridine were refluxed together in CH2Cl2 for 4 h to give 100% 3,3-dimethyl-5-trifluoromethanesulfonyloxy-7-ethyl-2,3-dihydrobenzoxazepine. The latter was heated with Me vinyl ketone,

(PPh<sub>3</sub>)<sub>2</sub>PdCl<sub>2</sub>, and Et<sub>3</sub>N in DMF at 70-75° for 5 h to give 96% (3E)-4-(3,3-dimethyl-7-ethyl-2,3-dihydrobenzoxepin-5-yl)buten-2-one.


IT 280585-64-0P

RL: SPN (Synthetic preparation); PREP (Preparation)  
(preparation of dimethylbenzoxepinyllalkenones as intermediates for antidiabetic pentadienoic acids)

RN 280585-64-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT:

4

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 6 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2005:523273 CAPLUS  
 DOCUMENT NUMBER: 143:53517  
 TITLE: Use of pentadienoic acid derivatives for the treatment of hyperuricemia  
 INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeiller, Jean-Jacques; Brutzkus, Bertrand  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 64 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 2  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
EP 1686983	A1	20060809	EP 2004-797525	20041102
EP 1686983	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1886129	A	20061227	CN 2004-80035212	20041102
BR 2004017003	A	20070116	BR 2004-17003	20041102
JP 2007512267	T	20070517	JP 2006-540224	20041102
IN 2006KN00961	A	20070420	IN 2006-KN961	20060418
MX 2006PA05788	A	20060714	MX 2006-PA5788	20060522
US 20070099854	A1	20070503	US 2006-580602	20060525
PRIORITY APPLN. INFO.:			EP 2003-292973	A 20031128
			US 2003-527773P	P 20031209
			WO 2004-EP12381	W 20041102
OTHER SOURCE(S):		MARPAT 143:53517		
GI				



AB The use of a pentadienoic acid derivative of formula I (e.g.,

(2E,4E)-5-(3,3-dimethyl-7-methoxy-2,3-dihydrobenzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid ) is claimed for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compns. for these prevention and/or treatment, comprising such a pentadienoic acid derivative

IT 280585-34-4, (2E,4E)-5-(2,3-Dihydro-3,3-Dimethyl-7-methoxy-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-39-9, (2Z,4E)-5-(3,3-Dimethyl-7-methoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-41-3, (2E,4E)-5-(3,3-Dimethyl-7,8-dimethoxy-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-43-5, (2E,4E)-5-(3,3-Dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-45-7, (2E,4E)-5-[3,3-Dimethyl-2,3-dihydro-7-(para-chlorobenzoyl)-1-benzoxepin-5-yl]-3-methylpenta-2,4-dienoic acid 280585-47-9, (2E,4E)-5-(3,3-Dimethyl-7-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-48-0, (2E,4E)-5-(3,3-Dimethyl-7,8-dichloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-50-4, (2E,4E)-5-(3,3-Dimethyl-7-bromo-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-51-5, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-8-chloro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-53-7, (2E,4E)-5-(3,3-Dimethyl-7-fluoro-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-55-9, (2E,4E)-5-(3,3-Dimethyl-7-trifluoromethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280585-57-1, (2E,4E)-5-(3,3-Dimethyl-7-phenyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 280586-03-0, (2E,4E)-5-(3,3,7-Trimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid 852550-63-1, (2E,4E)-5-(9-Methoxy-3,3-dimethyl-2,3-dihydro-1-benzoxepin-5-yl)-3-methylpenta-2,4-dienoic acid


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(use of pentadienoic acid derivs. for treatment of hyperuricemia)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-43-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 280585-45-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.






RN 280585-47-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-48-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-50-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-51-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-53-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-55-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-57-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-03-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852550-63-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:467780 CAPLUS

DOCUMENT NUMBER: 143:1300

TITLE: Use of pentadienoic acid derivatives for the prevention and/or the treatment of hyperuricemia  
 INVENTOR(S): Boizel, Robert; Fouqueray, Pascale; Guerrier, Daniel; Zeller, Jean-Jacques; Brutzkus, Bertrand

PATENT ASSIGNEE(S): Merck Sante, Fr.

SOURCE: Eur. Pat. Appl., 45 pp.

CODEN: EPXXDW

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1535612	A1	20050601	EP 2003-292973	20031128
EP 1535612	B1	20060913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 339200	T	20061015	AT 2003-292973	20031128
ES 2272926	T3	20070501	ES 2003-292973	20031128
AU 2004294686	A1	20050616	AU 2004-294686	20041102
CA 2547543	A1	20050616	CA 2004-2547543	20041102
WO 2005053676	A1	20050616	WO 2004-EP12381	20041102
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1686983	A1	20060809	EP 2004-797525	20041102
EP 1686983	B1	20070711		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS				
CN 1886129	A	20061227	CN 2004-80035212	20041102
BR 2004017003	A	20070116	BR 2004-17003	20041102
JP 2007512267	T	20070517	JP 2006-540224	20041102
AT 366570	T	20070815	AT 2004-797525	20041102
ES 2286692	T3	20071201	ES 2004-797525	20041102
IN 2006KN00961	A	20070420	IN 2006-KN961	20060418
MX 2006PA05788	A	20060714	MX 2006-PA5788	20060522
US 20070099854	A1	20070503	US 2006-580602	20060525
PRIORITY APPLN. INFO.:			EP 2003-292973	A 20031128
			US 2003-527773P	P 20031209
			WO 2004-EP12381	W 20041102

OTHER SOURCE(S): MARPAT 143:1300

AB Use of pentadienoic acid derivs. for the prevention and/or the treatment of hyperuricemia and/or associated disorders or diseases. The use of a pentadienoic acid derivative of formula (I) for the preparation of a medicament for the prevention or treatment of hyperuricemia and/or one or several associated disorders or diseases, and/or for reducing the serum uric acid level of a subject. Medical compns. for these prevention and/or treatment, comprising such a pentadienoic acid derivative

IT 280585-34-4 280585-39-9 280585-41-3


280585-43-5 280585-45-7 280585-47-9  
 280585-48-0 280585-50-4 280585-51-5  
 280585-53-7 280585-55-9 280585-57-1  
 280586-03-0 852550-63-1

RL: PAC (Pharmacological activity); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (use of pentadienoic acid derivs. for prevention and the treatment of hyperuricemia)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-43-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-45-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-47-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-48-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-50-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-51-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-53-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.






RN 280585-55-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-57-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-03-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 852550-63-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-9-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

1

THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 8 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:291092 CAPLUS

DOCUMENT NUMBER: 140:303553

TITLE: New metastable benzoxepine derivatives used for treating dyslipidemia, atherosclerosis, and diabetes, pharmaceutical compositions containing them, and their preparation processes by salt formation and acidulation

INVENTOR(S): Bosc, Nathalie; Festal, Didier; Boudet, Bernard

PATENT ASSIGNEE(S): Merck Sante, Fr.

SOURCE: Fr. Demande, 29 pp.

CODEN: FRXXBL

DOCUMENT TYPE: Patent

LANGUAGE: French


FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
FR 2845386	A1	20040409	FR 2002-12432	20021007
FR 2845386	B1	20060630		
CA 2502877	A1	20040415	CA 2003-2502877	20030901
WO 2004031166	A1	20040415	WO 2003-EP9680	20030901
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003264139	A1	20040423	AU 2003-264139	20030901
EP 1549630	A1	20050706	EP 2003-798880	20030901
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006503073	T	20060126	JP 2004-540566	20030901
US 20060041007	A1	20060223	US 2005-530571	20050407
PRIORITY APPLN. INFO.:			FR 2002-12432	A 20021007
			WO 2003-EP9680	W 20030901

OTHER SOURCE(S): MARPAT 140:303553

GI



AB The invention is directed to the preparation of new metastable benzoxepines I by salt formation of I and precipitation of I by acidulation of the aqueous salt


solution, and their use for treating dyslipidemia, atherosclerosis, and diabetes [n = 0, 1, or 2; R = independently alkyl, alkoxy, halo]. Thus, addition of aqueous NaOH solution to the stable form of I (R = OMe) (II), followed by acidulation with aqueous H<sub>2</sub>SO<sub>4</sub> afforded the metastable form of II in 99% yield (m.p. = 151-153° by DTA). The metastable form has a higher sp. surface area than the stable form, while their densities are comparable.

IT 280585-34-4P  
 RL: IMF (Industrial manufacture); RCT (Reactant); PREP (Preparation); RACT (Reactant or reagent)  
 (intermediate stable form, metastable product; preparation of metastable benzoxepines by salt formation and acidulation for treating dyslipidemia, atherosclerosis, and diabetes)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 9 OF 9 CAPLUS COPYRIGHT 2008 ACS on STN  
 ACCESSION NUMBER: 2000:457054 CAPLUS  
 DOCUMENT NUMBER: 133:89445  
 TITLE: Preparation of benzopyrans and benzoxepines and their  
 hypolipidemic and antidiabetic activity  
 INVENTOR(S): Brunet, Michel; Zeiller, Jean Jacques; Berthelon, Jean  
 Jacques; Contard, Francis; Augert, Guy; Guerrier,  
 Daniel  
 PATENT ASSIGNEE(S): Merck Patent G.m.b.H., Germany  
 SOURCE: PCT Int. Appl., 105 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: English  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000039113	A1	20000706	WO 1999-EP10114	19991220
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2787789	A1	20000630	FR 1998-16574	19981229
FR 2787789	B1	20020614		
CA 2356680	A1	20000706	CA 1999-2356680	19991220
BR 9916633	A	20010925	BR 1999-16633	19991220
EP 1140893	A1	20011010	EP 1999-967960	19991220
EP 1140893	B1	20030305		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
HU 2001004839	A2	20020429	HU 2001-4839	19991220
HU 2001004839	A3	20030128		
AU 759892	B2	20030501	AU 2000-24329	19991220
JP 2003517449	T	20030527	JP 2000-591024	19991220
RU 2228333	C2	20040510	RU 2001-120380	19991220
CN 1554651	A	20041215	CN 2004-10047645	19991220
MX 2001PA06590	A	20020311	MX 2001-PA6590	20010626
NO 2001003242	A	20010628	NO 2001-3242	20010628
US 6596758	B1	20030722	US 2001-869518	20010629
IN 2001KN00760	A	20050127	IN 2001-KN760	20010723
ZA 2001006177	A	20021028	ZA 2001-6177	20010726
HK 1047584	A1	20050527	HK 2002-108653	20021129
PRIORITY APPLN. INFO.:			FR 1998-16574	A 19981229
			WO 1999-EP10114	W 19991220

OTHER SOURCE(S): MARPAT 133:89445  
 GI



AB The title compds. I [X = O, S; A = (CH<sub>2</sub>)sCO(CH<sub>2</sub>)t, (CH<sub>2</sub>)sCR<sub>3</sub>R<sub>4</sub>(CH<sub>2</sub>)t and s = t = 0, or one of s and t is 0 and the other is 1; R<sub>1</sub>, R<sub>2</sub> = H, alkyl, alkenyl, alkynyl, etc.; R = halo, cyano, NO<sub>2</sub>, etc.] were prepared E.g., (2E,4E)-5-(2-pentyl-2H-1-benzopyran-3-yl)-3-methylpenta-2,4-dienoic acid was prepared The hypolipidemic and antidiabetic activity of I were investigated.


IT 280585-34-4P 280585-39-9P 280585-41-3P  
 280585-43-5P 280585-45-7P 280585-47-9P  
 280585-48-0P 280585-50-4P 280585-51-5P  
 280585-53-7P 280585-55-9P 280585-57-1P  
 280585-60-6P 280585-64-0P 280585-66-2P  
 280585-68-4P 280585-70-8P 280585-72-0P  
 280585-74-2P 280585-77-5P 280585-81-1P  
 280585-83-3P 280585-93-5P 280586-01-8P  
 280586-03-0P

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)  
 (preparation of benzopyrans and benzoxepines and their hypolipidemic and antidiabetic activity)

RN 280585-34-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-39-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2Z,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-41-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7,8-dimethoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-43-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-45-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-[7-(4-chlorobenzoyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-47-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-chloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-48-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7,8-dichloro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-50-4 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-bromo-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-51-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(8-chloro-7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.






RN 280585-53-7 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-fluoro-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-55-9 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-57-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3-dimethyl-7-phenyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-60-6 CAPLUS


CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-6-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 280585-64-0 CAPLUS  
 CN 2,4-Pentadienoic acid, 5-(7-ethyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.




RN 280585-66-2 CAPLUS  
 CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-7-(4-methoxyphenyl)-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



RN 280585-68-4 CAPLUS  
 CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7,8-tetramethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-70-8 CAPLUS

CN 2,4-Pentadienoic acid, 5-[8-(4-fluorophenyl)-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-72-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-8-methoxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-74-2 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(1-methylethyl)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-77-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-(trifluoromethoxy)-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-81-1 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-7-hydroxy-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-83-3 CAPLUS

CN 2,4-Pentadienoic acid, 5-[2,3-dihydro-3,3-dimethyl-7-[4-(trifluoromethyl)phenyl]-1-benzoxepin-5-yl]-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280585-93-5 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-cyclohexyl-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-01-8 CAPLUS

CN 2,4-Pentadienoic acid, 5-(7-ethoxy-2,3-dihydro-3,3-dimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)


Double bond geometry as shown.



RN 280586-03-0 CAPLUS

CN 2,4-Pentadienoic acid, 5-(2,3-dihydro-3,3,7-trimethyl-1-benzoxepin-5-yl)-3-methyl-, (2E,4E)- (CA INDEX NAME)

Double bond geometry as shown.



REFERENCE COUNT:

8

THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS  
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d his

(FILE 'HOME' ENTERED AT 09:09:40 ON 16 JUL 2008)

FILE 'REGISTRY' ENTERED AT 09:10:00 ON 16 JUL 2008

L1 STRUCTURE UPLOADED

L2 26 S L1 FULL

FILE 'CAPLUS' ENTERED AT 09:10:25 ON 16 JUL 2008

L3 9 S L2 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

50.01

228.58

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-7.20

-7.20

STN INTERNATIONAL LOGOFF AT 09:11:42 ON 16 JUL 2008